Jim Mason

The HITAR Institute Canada, Vancouver, BC, Canada
Author    Correspondence author
Cancer Genetics and Epigenetics, 2024, Vol. 12, No. 1   doi: 10.5376/cge.2024.12.0006
Received: 19 Dec., 2023    Accepted: 27 Jan., 2024    Published: 08 Feb., 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mason, 2024, High-throughput sequencing technology: a new chapter in epigenetics and disease research, Cancer Genetics and Epigenetics, 12(1): 47-54 (doi: 10.5376/cge.2024.12.0006)

This article outlines the applications of High-Throughput Sequencing (HTS) in identifying DNA methylation, histone modifications, non-coding RNA, and other aspects of epigenetics, as well as its role in understanding the genetic and epigenetic foundations of various diseases, especially cancer and hereditary diseases. It discusses in depth the significant role of HTS in disease diagnosis, treatment selection, and personalized medicine. Particularly in cancer treatment, HTS helps achieve more precise therapies by analyzing the genetic and epigenetic information of tumors. Despite challenges in data processing and analysis, advancements in technology and the development of new algorithms are continuously expanding its application scope. In summary, high-throughput sequencing technology is opening a new chapter in epigenetics and disease research, playing a key role in advancing our understanding of life sciences and driving medical innovation.

High-throughput sequencing; Epigenetics; Disease research; DNA methylation; Personalized medicine